MedTrace Logo

The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy

NCT02673515 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-05-28

Study results available
· View outcomes & findings →

Summary

InterFast is a Cohort study with an embedded randomized controlled pilot trial. Study participants will be healthy subjects and subjects who already practice Alternate Day Fasting. The trial will include 100 participants (50 Participants in Alternate Day Fasting group and 50 participants in the control group). Those participants in the control group will be asked to participate in a short randomized controlled trial, where they will be either allocated to an Alternative Day Fasting group or another control visit.

Conditions

  • Excessive Diet Restriction

Interventions

BEHAVIORAL

Alternate day fasting

Subjects are requested to fast every other day. Calorie free fluids are allowed.

Sponsors & Collaborators

  • University of Graz

    collaborator OTHER

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Harald Sourij, MD · Medical University of Graz, Auenbruggerplatz 15

  • Frank Madeo, PhD · Karl Franzens University Graz, Austria

  • Thomas R Pieber, MD · Medical University Graz, Austria

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2019-09-02
Completion
2019-09-02

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673515 on ClinicalTrials.gov